Pyxis Oncology (PYXS) Return on Equity (2021 - 2025)

Pyxis Oncology (PYXS) has 5 years of Return on Equity data on file, last reported at 0.01% in Q4 2025.

• Return on Equity for Q4 2025 came in at 0.01%, down 1.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.01% (down 1.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Equity eased to 0.01% in Q4 2025 per PYXS's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.01% in Q2 2021 and troughed at 0.01% in Q4 2025.
• A 5-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 0 bps in 2022 and fell as far as 1 bps in 2022.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2021, then increased by 6 bps to 0.01% in 2022, then grew by 16 bps to 0.01% in 2023, then declined by 0 bps to 0.01% in 2024, then slumped by 126 bps to 0.01% in 2025.
• Business Quant data shows PYXS's Return on Equity at 0.01% in Q4 2025, 0.01% in Q3 2025, and 0.01% in Q2 2025.